The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low?

Preventive Medicine

Volumn 48, Issue 5, 2009, Pages 407-410

  Porta, Miquel ^a,b,c  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c IL   (United States)

Author keywords

Adolescent; Cervical Intraepithelial Neoplasia prevention and control; Female; Genital Neoplasms, Female diagnosis economics *prevention and control; Human papillomavirus 16; Human papillomavirus 18; Humans; Immunization Programs; Papillomavirus Infections complications prevention and control; Papillomavirus Vaccines; Uterine Cervical Neoplasms prevention and control; Vaccination

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EDITORIAL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; UTERINE CERVIX CANCER;

FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PROGRAM EVALUATION; UTERINE CERVICAL NEOPLASMS;

EID: 65549130245     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2009.04.004     Document Type: Editorial

References (32)

1. Allen D., Mohllajee A.P., Shelton R.C., Othus M.K.D., Fontenot H.B., and Hanna R. Stage of adoption of the human papillomavirus vaccine among college women. Prev. Med. 48 (2009) 420-425
2. Arbyn M., Simoens C., Van Oyen H., et al. Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000). Prev. Med. 48 (2009) 438-443
3. Baden L.R., Curfman G.D., Morrissey S., et al. Human papillomavirus vaccine-opportunity and challenge [Editorial]. N. Engl. J. Med. 356 (2007) 1990-1991
4. Bosch F.X., Castellsagué X., and de Sanjosé S. HPV and cervical cancer: screening or vaccination?. Br. J. Cancer 98 (2008) 15-21
5. Boseley S., 2007. Alarm at 'battering ram' tactics over cervical cancer. Doctors urge caution as drug firms lobby hard for mass vaccination campaign. The Guardian, 26 March.
6. de Kok I.M., Habbema J.D., Mourits M.J., Coebergh J.W., and van Leeuwen F.E. Insufficient basis for the inclusion of human papillomavirus vaccination in the National Immunisation Programme in The Netherlands. Ned. Tijdschr. Geneeskd. 152 (2008) 2001-2004
7. de Sanjosé S., Díaz M., Castellsagué X., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7 (2007) 453-459
8. Dören M., in press. Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany. J Epidemiol Community Health, 63 (in press).
9. Dören M., Gerhardus A., Gerlach F.M., Glaeske G., Hornberg C., Kochen M.M., et al., 2009. Gebärmutterhalskrebs: Wie wirksam ist die HPV-Impfung? Dtsch Arztebl, 106 (8): A-330. Available at http://www.aerzteblatt.de/v4/archiv/artikel.asp?src=suche&p=gerhardus&id=63448. English translation available at: http://www.unibielefeld.de/gesundhw/ag3/downloads/Statement_HPV-vaccine.pdf.
10. Gould S.J. The hedgehog, the fox and the magister's pox. Mending and minding the misconceived gap between science and the humanities 102-104 (2004), Vintage, London 113-116
11. Haug C.J. Human papillomavirus vaccination-reasons for caution [Editorial]. N. Engl. J. Med. 359 (2008) 861-862
12. Howlett R.I., Miller A.B., Pasut G., and Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev. Med. 48 (2009) 432-437
13. Jain N., Euler G.L., Shefer A., Lu P., Yankey D., and Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev. Med. 48 (2009) 426-431
14. Lippman A., Melnychuk R., Shimmin C., et al. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ 177 (2007) 484-487
15. In: Marinker M. (Ed). Constructive conversations about health. Policy and values (2006), Radcliffe Publishing, Oxford & Seattle
16. Markowitz L.E., Unger E.R., and Saraiya M. Primary and secondary prevention of cervical cancer-opportunities and challenges. J. Natl. Cancer Inst. 101 (2009) 439-440
17. Márquez-Calderón S., González López-Valcárcel B., and Segura A. Medical societies' recommendations for immunization with human papillomavirus vaccine and disclosure of conflicts of interests. Prev. Med. 48 (2009) 449-453
18. Merz M. Knowledge construction. In: Restivo S. (Ed). Science, technology, and society. An encyclopedia (2005), Oxford University Press, Oxford
19. Minnesota Department of Health, 2008. Infectious Disease Epidemiology, Prevention and Control, Immunization, Tuberculosis and International Health. Commissioner's Office. Human Papillomavirus Vaccine. Report to the Minnesota Legislature 2008. St. Paul, Minnesota, 1 Febr. 2008. Available at: www.health.state.mn.us.
20. Morabia A. Should an epidemiologist also have been awarded the 2008 Nobel Prize in Medicine? [Editorial]. J. Epidemiol. Community Health 63 (2009) 177-178
21. In: Porta M. (Ed). A dictionary of epidemiology. 5th edition (2008), Oxford University Press, New York 83-84 133, 139, 233
22. Porta M., and Álvarez-Dardet C. Epidemiology: bridges over (and across) roaring levels [Editorial]. J. Epidemiol. Community Health 52 (1998) 605
23. Porta M., Hernández-Aguado I., Lumbreras B., and Crous-Bou M. 'Omics' research, monetization of intellectual property and fragmentation of knowledge: can clinical epidemiology strengthen integrative research?. J. Clin. Epidemiol. 60 (2007) 1220-1225
24. Porta M., González López-Valcárcel B., Márquez Calderón S., and Artazcoz L. Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available?. J. Epidemiol. Community Health 62 (2008) 667
25. Puig-Junoy J., and González López-Valcárcel B. Economic evaluations of massive HPV vaccination: Within-study and between study variations in incremental cost per QALY gained. Prev. Med. 48 (2009) 444-448
26. Rabin R.C. Benefits of mammogram under debate in Britain. N.Y. Times (2009) D5 March 31
27. Tuma R.S. Assessing the HPV vaccine: researchers confront complex interplay of factors. J. Natl. Cancer Inst. 101 (2009) 444
28. Udesky L. Push to mandate HPV vaccine triggers backlash in USA. Lancet 369 (2007) 979-980
29. Waller J., Marlow L.A.V., and Wardle J. Anticipated shame and worry following an abnormal Pap test result: the impact of information about HPV. Prev. Med. 48 (2009) 415-419
30. Wheeler C.M., Hunt W.C., Joste N.E., Key C.R., Quint W.G.V., and Castle P.E. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J. Natl. Cancer Inst. 101 (2009) 475-487
31. Wynia M.K. Public health, public trust and lobbying. Am. J. Bioeth. 7 (2007) 4-7
32. Ziarnowski K.L., Brewer N.T., and Weber B. Present choices, future outcomes: anticipated regret and HPV vaccination. Prev. Med. 48 (2009) 411-414